a phase II controlled clinical trial, set forth astonishing results in a class of patients termed factually terminal [stage 4], who had become unresponsive, or had failed to respond initially, to conventional therapy: 58 percent demonstrated anticachexia response (weight gain, performance status improvement, normalization of the laboratory indices, etc.), and 35 percent showed antitumor response (tumor regression or stabilization); one year later the initial series of 48 patients was enlarged to 95 patients, with essentially the same results.

Secondly, Internet sources have implicated hydrazine sulfate to be toxic or carcinogenic.

Although hydrazine sulfate is carcinogenici.e., can cause cancerin some weanling mice given the drug in their drinking water since birth, presented a Brief Communication (and accompanying editorial) in its December 5, 2000 issue, of a single patient who allegedly died of fatal hepatorenal failure as a result of HS therapy.

The third, a small study of 29 patients conducted at Memorial Sloan-Kettering Cancer Center, totally uncontrolled for patient selection, drug dosage and treatment schedule, and prior and concurrent therapy, found no long-term improvements (although transient response was recorded).

The ACS stated: After careful study of the literature and other available information, the American Cancer Society does not have evidence that Hydrazine Sulfate is of any objective benefit in the treatment of cancer in human beings.

It must be stressed that no legitimate researcher of incompatibilityin the trial of a test drug.

Use of an incompatible agent in a drug test, which acts to cause a negative study, can only be the result of incompetence or deliberateness.

Nevertheless, although arrangements had been made through the Soviet and American governments to have Dr.

Gershanovich come to this country to discuss these results, after traveling more than 7,000 miles he was not permitted to present his paper orally at the annual scientific meetings of the American Association for Cancer Research in New Orleans .

References are used in support of the events, happenings and details of this expanded statement. Hydrazine sulfate (HS), an inexpensive, mass-produced chemical compound used for many industrial applications, was first proposed as an anticachexia agent based on its inhibition of the gluconeogenic enzyme, phosphoenolpyruvate carboxykinase (PEP CK). This was exactly opposite of what was communicated to Congressman Hanley.